NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its earnings results on Tuesday, August, 6th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.27. The biotechnology company earned $44.40 million during the quarter, compared to analysts' expectations of $46.98 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. The business's revenue was down 22.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

3 analysts have issued 12-month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $100.00 to $120.00. On average, they expect Enanta Pharmaceuticals' share price to reach $112.3333 in the next twelve months. This suggests a possible upside of 58.2% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Enanta Pharmaceuticals.

News stories about ENTA stock have trended negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Enanta Pharmaceuticals.

Enanta Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,230,300 shares, an increase of 15.7% from the July 31st total of 1,928,200 shares. Based on an average daily trading volume, of 192,500 shares, the short-interest ratio is presently 11.6 days. Approximately 14.1% of the shares of the company are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Allakos (ALLK), FibroGen (FGEN), Alkermes (ALKS), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Ford Motor (F), Cronos Group (CRON), Dollar Tree (DLTR), Intercept Pharmaceuticals (ICPT), Gilead Sciences (GILD), NVIDIA (NVDA), Zoetis (ZTS), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU) and Celgene (CELG).

Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.18%), BlackRock Inc. (13.17%), Vanguard Group Inc. (8.24%), Price T Rowe Associates Inc. MD (7.77%), Farallon Capital Management LLC (4.88%) and Janus Henderson Group PLC (4.80%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Invesco Ltd., Renaissance Technologies LLC, Bank of New York Mellon Corp, First Manhattan Co., Chicago Equity Partners LLC, AQR Capital Management LLC and Trexquant Investment LP. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathalie Adda, Nathaniel S Gardiner, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, Janus Henderson Group PLC, Los Angeles Capital Management & Equity Research Inc., Jacobs Levy Equity Management Inc., JPMorgan Chase & Co. and BlackRock Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $71.01.

Enanta Pharmaceuticals has a market capitalization of $1.40 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]